Karla Helvie

3.5k total citations
14 papers, 240 citations indexed

About

Karla Helvie is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Karla Helvie has authored 14 papers receiving a total of 240 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Cancer Research, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Oncology. Recurrent topics in Karla Helvie's work include Advanced Breast Cancer Therapies (8 papers), Cancer Genomics and Diagnostics (8 papers) and HER2/EGFR in Cancer Research (3 papers). Karla Helvie is often cited by papers focused on Advanced Breast Cancer Therapies (8 papers), Cancer Genomics and Diagnostics (8 papers) and HER2/EGFR in Cancer Research (3 papers). Karla Helvie collaborates with scholars based in United States, Brazil and France. Karla Helvie's co-authors include Nancy U. Lin, Nikhil Wagle, Seth A. Wander, Eric P. Winer, Ofir Cohen, Utthara Nayar, Samuel S. Freeman, Lori Marini, Nelly Oliver and X. Cynthia and has published in prestigious journals such as Nature Communications, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Karla Helvie

13 papers receiving 238 citations

Peers

Countries citing papers authored by Karla Helvie

Since Specialization

Citations

This map shows the geographic impact of Karla Helvie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karla Helvie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karla Helvie more than expected).

Fields of papers citing papers by Karla Helvie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karla Helvie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karla Helvie. The network helps show where Karla Helvie may publish in the future.

Co-authorship network of co-authors of Karla Helvie

This figure shows the co-authorship network connecting the top 25 collaborators of Karla Helvie. A scholar is included among the top collaborators of Karla Helvie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karla Helvie. Karla Helvie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial 2024 ·Nature Communications ·Jorge Gómez Tejeda Zañudo, Romualdo Barroso‐Sousa, Esha Jain, Qingchun Jin, Tianyu Li, Jorge E. Buendia-Buendia, (unknown), Daniel L. Abravanel, Arlindo R. Ferreira, Eileen Wrabel, Karla Helvie, Melissa E. Hughes, Ann H. Partridge, Beth Overmoyer, Nancy U. Lin, Nabihah Tayob, Sara M. Tolaney, Nikhil Wagle	15
2	Abstract P4-01-06: Genomic and transcriptomic analysis reveals known and novel resistance mechanisms to CDK4/6 inhibitors and sensitivity factors for the response to triplet therapy (palbociclib + everolimus + exemestane) in a phase I/IIb study in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i) 2022 ·Cancer Research ·Jorge Gómez Tejeda Zañudo, Romualdo Barroso‐Sousa, Esha Jain, Jorge E. Buendia-Buendia, Tianyu Li, Nabihah Tayob, (unknown), (unknown), Arlindo R. Ferreira, Daniel L. Abravanel, Karla Helvie, Ann H. Partridge, Beth Overmoyer, Eric P. Winer, Nikhil Wagle, Sara M. Tolaney	2
3	Newly Diagnosed Patients with Inflammatory Bowel Disease: The Relationship Between Perceived Psychological Support, Health-Related Quality of Life, and Disease Activity 2021 ·Health Equity ·(unknown), (unknown), Rie Suzuki, Karla Helvie, Jeremy Adler, (unknown), Ellen M. Zimmermann	10
4	A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer 2021 ·Breast Cancer Research and Treatment ·(unknown), Inês Vaz-Luís, Tianyu Li, Nabihah Tayob, Esha Jain, Karla Helvie, Jorge E. Buendia-Buendia, Erin Shannon, Steven J. Isakoff, Nadine Tung, Ian E. Krop, Nancy U. Lin, Nikhil Wagle, Rachel A. Freedman	4
5	Abstract GS2-02: Acquired activating mutations in RTKs confer endocrine resistance in ER+ metastatic breast cancer through ER-reprogramming, MAPK signaling, and an induced stem-like cell state 2020 ·Cancer Research ·Ofir Cohen, Pingping Mao, Utthara Nayar, (unknown), Dewey Kim, Esha Jain, Karla Helvie, Daniel L. Abravanel, Kailey J. Kowalski, (unknown), Samuel S. Freeman, (unknown), Seth A. Wander, Adrienne G. Waks, Gad Getz, Aviv Regev, (unknown), Nancy U. Lin, Nikhil Wagle	1
6	Abstract P5-11-04: A phase I/IIb study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): Results of the phase II study 2020 ·Cancer Research ·Romualdo Barroso‐Sousa, Tianyu Li, Lorenzo Trippa, (unknown), Chelsea Andrews, Arlindo R. Ferreira, Karla Helvie, Ann H. Partridge, Beth Overmoyer, Eric P. Winer, Nikhil Wagle, Sara M. Tolaney	2
7	Reversion and non-reversion mechanisms of resistance (MoR) to PARP inhibitor (PARPi) or platinum chemotherapy (chemotx) in patients (pts) with BRCA1/2-mutant metastatic breast cancer (MBC). 2019 ·Journal of Clinical Oncology ·Adrienne G. Waks, Ofir Cohen, Bose Kochupurakkal, Dewey Kim, Seth A. Wander, Jorge E. Buendia-Buendia, Karla Helvie, Ursula A. Matulonis, Ian E. Krop, Sara M. Tolaney, Eric P. Winer, Alan D. D’Andrea, Geoffrey I. Shapiro, Nancy U. Lin, Nikhil Wagle	2
8	Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies 2018 ·Nature Genetics ·Utthara Nayar, Ofir Cohen, (unknown), Michael S. Cuoco, Adrienne G. Waks, Seth A. Wander, Corrie Painter, Samuel S. Freeman, Nicole S. Persky, Lori Marini, Karla Helvie, Nelly Oliver, Orit Rozenblatt–Rosen, X. Cynthia, Aviv Regev, Eric P. Winer, Nancy U. Lin, Nikhil Wagle	159
9	Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). 2018 ·Journal of Clinical Oncology ·Seth A. Wander, Ofir Cohen, Gabriela N. Johnson, Dewey Kim, Flora Luo, Pingping Mao, Utthara Nayar, Karla Helvie, Lori Marini, Samuel S. Freeman, Gad Getz, Levi A. Garraway, Eric P. Winer, Nancy U. Lin, Nikhil Wagle	11
10	Abstract 4952: Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to ER-directed therapies 2018 ·Cancer Research ·Utthara Nayar, Ofir Cohen, (unknown), Adrienne G. Waks, Seth A. Wander, Corrie Painter, Samuel S. Freeman, Priyanka Ram, Nicole S. Persky, Lori Marini, Karla Helvie, Nelly Oliver, X. Cynthia, Eric P. Winer, Nancy U. Lin, Nikhil Wagle	2
11	A cancer precision medicine platform for multiple simultaneous genomic assays from metastatic biopsies (bx) in ER+ metastatic breast cancer. 2016 ·Journal of Clinical Oncology ·Nikhil Wagle, Karla Helvie, Maxwell R. Lloyd, Lori Marini, Adrienne G. Waks, Ofir Cohen, Coyin Oh, Carrie Sougnez, Nelly Oliver, (unknown), Asaf Rotem, Parin Shah, Neal I. Lindeman, Ian E. Krop, Levi A. Garraway, Eric P. Winer, Nancy U. Lin	0
12	Mechanisms of resistance (MoR) to DNA damaging therapy (tx) in BRCA1/2-deficient (d) metastatic breast cancer (MBC). 2016 ·Journal of Clinical Oncology ·Adrienne G. Waks, Ofir Cohen, Karla Helvie, Maxwell R. Lloyd, Lori Marini, Coyin Oh, Nelly Oliver, Neal I. Lindeman, Ursula A. Matulonis, Ian E. Krop, Levi A. Garraway, Eric P. Winer, Nancy U. Lin, Nikhil Wagle	1
13	Effects of Inflammatory Bowel Disease on Students' Adjustment to College 2014 ·Clinical Gastroenterology and Hepatology ·(unknown), Jeremy Adler, (unknown), (unknown), Karla Helvie, Rafat Rizk, Ellen M. Zimmermann	29
14	474 Magnetization-Transfer MRI As a Non-Invasive Method of Assessing Fibrotic Intestinal Strictures in Patients With Crohn's Disease 2013 ·Gastroenterology ·Karla Helvie, (unknown), Mahmoud M. Al-Hawary, Jordi Rimola, (unknown), Jeremy Adler, Ellen M. Zimmermann	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact